#152627

Anti-V(beta)3 T cell receptor (TcR) [JOVI.3]

Cat. #152627

Anti-V(beta)3 T cell receptor (TcR) [JOVI.3]

Cat. #: 152627

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 3-4 weeks

Target: V(beta)3 T cell receptor (TcR)

Class: Monoclonal

Application: FACS ; IHC ; IP ; Fn

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Mike Owen

Institute: Cancer Research UK, London Research Institute: Lincoln's Inn Fields

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-V(beta)3 T cell receptor (TcR) [JOVI.3]
  • Research fields: Cell biology;Immunology;Immuno-oncology;Immunophenotyping
  • Clone: JOVI.3
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Reactivity: Human
  • Host: Mouse
  • Application: FACS ; IHC ; IP ; Fn
  • Description: Monoclonal antibody used in the study of T cell diseases, and as a CAR therapy in T cell lymphoma/leukaemia. Background and Research Application The T cell receptor is heterodimer of alpha/beta or gamma/delta chains, expressed on all mature T cells. TCR's recognise antigen peptides bound to MHC molecules, providing the basis of antigen specific response by T cells. JOVI.3 can be used for studies of T cell mediated diseases, including autoimmunity and allergy. The antibody recognises any human T cell receptor that has the V beta 3 region, staining 50-75% of peripheral blood T cells and T cell lines.
  • Immunogen: Thymus, spleen and mesenteric lymph nodes isolated from a mouse transgenic for human Vb3 TcR.
  • Immunogen uniprot id: P09693
  • Isotype: IgG2a
  • Myeloma used: P3/NS1/1-Ag4.1
  • Recommended controls: CD3 positive PBMCs

Target Details

  • Target: V(beta)3 T cell receptor (TcR)
  • Tissue cell line specificity: CD3 positive PBMCs
  • Target background: Monoclonal antibody used in the study of T cell diseases, and as a CAR therapy in T cell lymphoma/leukaemia. Background and Research Application The T cell receptor is heterodimer of alpha/beta or gamma/delta chains, expressed on all mature T cells. TCR's recognise antigen peptides bound to MHC molecules, providing the basis of antigen specific response by T cells. JOVI.3 can be used for studies of T cell mediated diseases, including autoimmunity and allergy. The antibody recognises any human T cell receptor that has the v?3 region, staining 50-75% % of peripheral blood T cells and T cell lines.

Applications

  • Application: FACS ; IHC ; IP ; Fn

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: Store at -20° C frozen. Avoid repeated freeze / thaw cycles
  • Shipping conditions: Shipping at 4° C

References

  • Viguier et al. 2015. J Invest Dermatol. 135(2):418-24. PMID: 25207820.
  • Peripheral and local human papillomavirus 16-specific CD8+ T-cell expansions characterize erosive oral lichen planus.
  • San Jos et al. 1999. J Biol Chem. 274(47):33740-6. PMID: 10559266.
  • Receptor engagement transiently diverts the T cell receptor heterodimer from a constitutive degradation pathway.
  • Sahuquillo et al. 1998. J Exp Med. 187(8):1179-92. PMID: 9547330.
  • T cell receptor (TCR) engagement in apoptosis-defective, but interleukin 2 (IL-2)-producing, T cells results in impaired ZAP70/CD3-zeta association.
  • Viney et al. 1992. Hybridoma. 11(6):701-13. PMID: 1284120.
  • Generation of monoclonal antibodies against a human T cell receptor beta chain expressed in transgenic mice.